Novel Therapies and Technologies Working Party
The Novel Therapies and Technologies Working Party (NTWP) provides recommendations to the Committee for Veterinary Medicinal Products (CVMP) on all matters relating to veterinary novel therapies and technologies.
Responsibilities and composition
The group is involved in activities such as preparing and updating European and international guidelines, and providing recommendations and advice to the CVMP on topics related to novel veterinary therapies and technologies.
It also addresses queries from other EMA committees, working parties, the European Union (EU) Member States and other parties, and contributes to workshops and training sessions on the evaluation of novel veterinary therapies and technologies.
It contributes towards establishing a future regulatory framework for the authorisation of novel veterinary therapies and technologies in the EU, and implementing the EMA Regulatory Science Strategy to 2025 and the European medicines agencies network strategy.
The NTWP aims to foster and support innovation, to enable the timely availability of novel veterinary therapies and technologies in the EU.
The NTWP is composed of European experts nominated and appointed by CVMP. Additional observers may also attend the meetings of the working party, if required.
More information on the NTWP's responsibilities, composition, procedures and activities is available in the following documents:
Mandate, objectives and rules of procedure for the CVMP Veterinary Novel Therapies & Technologies Working Party (NTWP) (PDF/223.97 KB)
First published: 15/09/2021
Work plan for the CVMP Novel Therapies & Technologies Working Party (NTWP) 2023 (PDF/222.03 KB)Adopted
First published: 16/12/2022
Below (in alphabetical order of surname) are the current members of the working group. The members' declarations of interests are available in the European expert list.